Skip to main content

Medical Oncology Clinic

The Institut Bordet Medical Oncology Clinic has a number of roles:

  • diagnosis and therapeutic care of patients with solid tumours
  • overseeing administration of cancer medication for in-patients and out-patients
  • monitoring patients during and after their treatment.

The Clinic takes a multidisciplinary approach. Therapeutic decisions are made in consultation with other specialist doctors and healthcare professionals involved in the patient’s care.
The aim is that patients should be monitored in all respects, including psychologically.

The Medical Oncology Clinic forms an integral part of the Department of Oncological Medicine. It is also very active in clinical research (particularly in the development of new medication) and translational research. At the Clinic, research is integrated into the care provided, enabling patients to benefit from the latest diagnostic and therapeutic advances, well before these become part of clinical routine.

Research projects

Project 1

AURORA Programme aimed at understanding the molecular characteristics of recurrent and metastatic breast cancer early in the evolution of metastatic disease.

Project 2

CHARACTERIZATION OF ENDOCRINE RESISTANT Luminal Breast Cancer using spatial transcriptomics AND epigenetic ANALYSIS. 
  • Project leaders : Christos Sotiriou, Françoise Rothé and Mattia Rediti
  • Collaborations : 
    - Dr François Fuks, Laboratory of Cancer Epigenetics, ULB-Cancer Research Center (U-CRC), Université libre de Bruxelles
    - Prof Lundeberg at the SciLife laboratory, Stockholm, Sweden
    - Dr Frédérick Libert, ULB/VUB Brightcore sequencing facility

Project 3

ZENITH: A PHASE 2 STUDY OF ZEN003694 IN COMBINATION WITH TALAZOPARIB IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER (BRCA1 OR BRCA2 NON MUTATED)
  • Project leader : Philippe Aftimos 
  • Collaborations : International clinical study
  • Funding (or) Support : Zenith Epigenetics Ltd.

Project 4

MULTICENTRIC PHASE II SINGLE-ARM STUDY OF NIVOLUMAB IN PATIENTS WITH TYPE B3 THYMOMA AND THYMIC CARCINOMA PREVIOUSLY TREATED WITH CHEMOTHERAPY
  • Project leader : Thierry Berghmans
  • Collaborations : International clinical study
  • Funding (or) Support : EORTC

Project 5

AURA : Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers

Project 6

MIME-A Abémaciclib
Multiorgan Metabolic imaging response assessment of Abemaciclib

Our team

Head of the Medical Oncology Clinic
Pr A. Awada

Solid Tumours / New Innovative drugs
Pr A. AwadaDr Ph. AftimosDr N. Kotecki

Solid and RareTumours
Pr A. AwadaDr Ch. Jungels

Breast Oncology
Pr M. PiccartDr D. de Valeriola
Dr Ph. AftimosDr A. Gombos
Pr Ch. SotiriouDr E. de Azambuja
Dr M. IgnatiadisDr F. Lebrun 
Dr L. BuisseretDr L. Polastro
Pr A. DrowartDr D. t’Kint de Roodenbeke

Oncogeriatrics 
Dr L. Dal LagoPr Th. Pepersack (geriatrician)

Cervico-facial Oncology  
Dr Y. Lalami

Skin Tumour Oncology                
Dr J. Kerger / Pr A. Awada
Pr A. Drowart
Dr M. Suppa

Digestive Oncology / Gastroenterology / Endoscopy
Dr A. HendliszDr A. Deleporte
Dr F. Sclafani

Gynaecological Oncology
Dr J. KergerDr L. Polastro
Dr F. LebrunPr A. Drowart

Thoracic Oncology
Pr Th. Berghmans

Urogenital, Bone and Soft Tissue Oncology
Dr Th. Gil,
Dr Ch. Jungels (sarcomas)
Dr N. Martínez-Chanza (urogenital tumors)

Dr S. Sideris (urogenital tumors)

Oncological Day Hospital
Dr D. de Valeriola
Dr Y. Lalami, Dr L. Polastro

Oncogenetics
Dr D. t’Kint de Roodenbeke

Psychooncology
Pr D. Razavi, Dr G. StefosDr X. Bondenet

Supportive and Palliative Cares / Pain Clinic
Dr I. Libert, Pr A. Drowart (mobile unite)

Consultants :    
Pr J. Klastersky (internal medicine/oncology)
Pr B. Desmarez (gastroenterology/endoscopy)
Dr Z. El Ali (medical oncology)
Dr E. Girard (oncologie médicale/digestive)
Dr P. Gkolfakis (gastroentérologie/endoscopie)
Dr Y. Gökburun (gastroenterology/medical oncology)
Dr D. Levacq (medical oncology/oncogenetics)
Dr A. Lepida (gastroenterology/hepatology)
Dr H. Louis (gastroenterology/digestive functional disorders)
Dr F. Mana (gastroenterology/endoscopy)
Pr A. Van Gossum (endoscopy/gastroenterology/nutrition)

 Scientific publications

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.

Authors : Piccart-Gebhart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, Restuccia E, Jerusalem G, Dent S, Reaby L, Bonnefoi H, Krop I, Liu TW, Pienkowski T, Toi M, Wilcken N, Andersson M, Im YH, Tseng LM, Lueck HJ, Colleoni M, Monturus E, Sicoe M, Guillaume S, Bines J, Gelber Rd, Viale G, Thomssen C
Year : 2021
Journal : J Clin Oncol
Pages : JCO2001204

Safety, anti-tumor activity and T-cell responses in a dose-ranging phase 1 trial of the oncolytic peptide LTX-315 in patients with solid tumors.

Authors : Spicer J, Marabelle A, Baurain JF, Jebsen NL, Jøssang DE, Awada A, Kristeleit R, Loirat D, Lazaridis G, Jungels C, Brunsvig P, Nicolaisen B, Saunders A, Patel H, Galon J, Hermitte F, Camilio KA, Mauseth B, Sundvold V, Sveinbjørnsson B, Rekdal Ø
Year : 2021
Journal : Clin Cancer Res

Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.

Authors : Lebbé C, Italiano A, Houédé N, Awada A, Aftimos P, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Raymond E, Faivre S, Pages C, Gomez-Roca C, Schueler A, Goodstal S, Massimini G, Delord JP
Year : 2021
Journal : Target Oncol
Volume : 16
Pages : 47-57

Tolerability and toxicity of trastuzumab or trastuzumab?+?lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).

Authors : Pondé N, Agbor-Tarh D, Dal Lago L, Korde LA, Hilbers F, Jackisch C, Werner O, Gelber Rd, Jatoi A, Dueck AC, Moreno-Aspitia A, Sotiriou C, de Azambuja E, Piccart-Gebhart M
Year : 2021
Journal : Breast Cancer Res Treat
Volume : 185
Pages : 107-116

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours.

Authors : van Bussel MTJ, Awada A, de Jonge MJA, Mau-Sørensen M, Nielsen D, Schöffski P, Verheul HMW, Sarholz B, Berghoff K, El Bawab S, Kuipers M, Damstrup L, Diaz-Padilla I, Schellens JHM
Year : 2021
Journal : Br J Cancer
Volume : 124
Pages : 728-735